Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia.
作者信息
Hartley Iris R, Miller Carole B, Papadakis Georgios Z, Bergwitz Clemens, Del Rivero Jaydira, Blau Jenny E, Florenzano Pablo, Berglund Jason A, Tassone Jing, Roszko Kelly L, Moran Susan, Gafni Rachel I, Isaacs Randi, Collins Michael T
机构信息
National Institute of Dental and Craniofacial Research, Bethesda, MD.
Ascension Saint Agnes Cancer Institute, Baltimore, MD.
出版信息
N Engl J Med. 2020 Oct 1;383(14):1387-1389. doi: 10.1056/NEJMc2020399. Epub 2020 Sep 9.
Abstract
摘要
相似文献
1
Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia.靶向成纤维细胞生长因子受体阻断剂治疗肿瘤诱导的骨软化症
N Engl J Med. 2020 Oct 1;383(14):1387-1389. doi: 10.1056/NEJMc2020399. Epub 2020 Sep 9.
2
Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor.新型成纤维细胞生长因子受体酪氨酸激酶抑制剂英菲格拉替尼的眼部不良反应
Ophthalmology. 2021 Apr;128(4):624-626. doi: 10.1016/j.ophtha.2020.08.026. Epub 2020 Sep 1.
3
Octreotide therapy for tumor-induced osteomalacia.奥曲肽治疗肿瘤诱导的骨软化症。
N Engl J Med. 2001 Dec 27;345(26):1883-8. doi: 10.1056/NEJMoa010839.
4
Burosumab treatment of tumour-induced osteomalacia from a rib lesion.布罗索尤单抗治疗肋骨病变所致肿瘤性骨软化症。
BMJ Case Rep. 2025 May 15;18(5):e265058. doi: 10.1136/bcr-2025-265058.
5
[Bone and calcium metabolism associated with malignancy. Tumor-induced osteomalacia.].[与恶性肿瘤相关的骨与钙代谢。肿瘤诱导的骨软化症。]
Clin Calcium. 2018;28(11):1451-1455.
6
Tumor-Induced Osteomalacia.肿瘤相关性骨软化症。
Calcif Tissue Int. 2021 Jan;108(1):128-142. doi: 10.1007/s00223-020-00691-6. Epub 2020 Jun 5.
7
Reports of 17 Chinese patients with tumor-induced osteomalacia.17例肿瘤诱导性骨软化症中国患者的报告。
J Bone Miner Metab. 2017 May;35(3):298-307. doi: 10.1007/s00774-016-0756-9. Epub 2016 Apr 16.
8
Tumor-induced osteomalacia.肿瘤相关性骨软化症。
Panminerva Med. 2024 Jun;66(2):188-197. doi: 10.23736/S0031-0808.23.05047-4. Epub 2023 Dec 21.
9
Model-Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor-Induced Osteomalacia.基于模型的方法为儿科和成年肿瘤性骨软化症患者推荐布罗索尤单抗的给药方案。
Clin Pharmacol Ther. 2024 Dec;116(6):1606-1614. doi: 10.1002/cpt.3468. Epub 2024 Oct 24.
10
[Osteomalacia due to phosphate deficiency caused by a tumor. Focus on FGF23 in physiology and clinic].[肿瘤所致磷缺乏引起的骨软化症。聚焦于成纤维细胞生长因子23的生理与临床]
Lakartidningen. 2012;109(32-33):1414-6.
引用本文的文献
1
Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.基因融合作为软组织肉瘤潜在的治疗靶点
Biomolecules. 2025 Jun 19;15(6):904. doi: 10.3390/biom15060904.
2
Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients.培米替尼治疗肝内胆管癌：两例北欧患者的病例报告
Acta Oncol. 2025 Apr 15;64:534-539. doi: 10.2340/1651-226X.2025.42073.
3
Treatment Advances in Tumor-Induced Osteomalacia.肿瘤诱导性骨软化症的治疗进展
Calcif Tissue Int. 2025 Jan 4;116(1):24. doi: 10.1007/s00223-024-01317-x.
4
Phosphaturic mesenchymal tumor of the popliteal fossa: a case report and literature review.腘窝磷酸尿性间叶肿瘤：一例报告及文献复习
Front Oncol. 2024 Dec 19;14:1501499. doi: 10.3389/fonc.2024.1501499. eCollection 2024.
5
Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia.获得性成纤维细胞生长因子 23 相关低磷血症性骨软化症。
Endocrinol Metab (Seoul). 2024 Apr;39(2):255-261. doi: 10.3803/EnM.2023.1908. Epub 2024 Mar 11.
6
[Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases].[成纤维细胞生长因子23分泌性肿瘤的临床特征、诊断与治疗：40例临床病例系列]
Probl Endokrinol (Mosk). 2023 Nov 10;69(5):25-38. doi: 10.14341/probl13221.
7
Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses.英菲格拉替尼，一种选择性 FGFR1-3 酪氨酸激酶抑制剂，高剂量会改变牙牙槽发育。
Dev Dyn. 2023 Dec;252(12):1428-1448. doi: 10.1002/dvdy.642. Epub 2023 Jul 12.
8
Atypical Fragility Fractures due to Bony or Soft Tissue Phosphaturic Mesenchymal Tumors: A Report of Two Cases.骨或软组织磷酸酶性间叶肿瘤所致非典型脆性骨折：2例报告
Case Rep Orthop. 2023 Apr 12;2023:5614065. doi: 10.1155/2023/5614065. eCollection 2023.
9
Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source.HRAS 介导的皮肤性骨骼低磷血症综合征的鼠模型提示骨骼是 FGF23 过多的来源。
J Clin Invest. 2023 May 1;133(9):e159330. doi: 10.1172/JCI159330.
10
Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.英菲格拉替尼可降低肿瘤诱导的骨软化症中纤维母细胞生长因子23（FGF23）水平并提高血磷水平。
JBMR Plus. 2022 Jul 22;6(8):e10661. doi: 10.1002/jbm4.10661. eCollection 2022 Aug.
本文引用的文献
1
Tumour-induced osteomalacia.肿瘤相关性骨软化症。
Nat Rev Dis Primers. 2017 Jul 13;3:17044. doi: 10.1038/nrdp.2017.44.
2
Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.FN1-FGFR1 和新型 FN1-FGF1 融合基因在一系列大型磷酸尿素质瘤中的特征。
Mod Pathol. 2016 Nov;29(11):1335-1346. doi: 10.1038/modpathol.2016.137. Epub 2016 Jul 22.
3
Tumor localization and biochemical response to cure in tumor-induced osteomalacia.肿瘤所致骨软化症中的肿瘤定位和生化反应。
J Bone Miner Res. 2013 Jun;28(6):1386-98. doi: 10.1002/jbmr.1881.
4
Regulation and function of the FGF23/klotho endocrine pathways.成纤维细胞生长因子 23（FGF23）/klotho 内分泌途径的调节和功能。
Physiol Rev. 2012 Jan;92(1):131-55. doi: 10.1152/physrev.00002.2011.
5
Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia.马萨诸塞州总医院病例记录。病例33 - 2011。一名56岁的低磷血症男性。
N Engl J Med. 2011 Oct 27;365(17):1625-35. doi: 10.1056/NEJMcpc1104567.
Zotero 插件